Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Adenocarcinoma; Chemotherapy Effect; Borderline Resectable Pancreatic Adenocarcinoma; Pancreatectomy Intervention: Drug: Folfirinox Sponsors: Oslo University Hospital; Haukeland University Hospital; St. Olavs Hospital; University Hospital of North Norway; Helse Stavanger HF Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Norway Health | Pancreas | Pancreatic Cancer | Research